Table I.
Characteristic | No. |
---|---|
Median age, years (range) | 65 (34–81) |
Gender | |
Female | 7 |
Male | 10 |
Performance status (ECOG) | |
0 | 5 |
1 | 12 |
Prior chemotherapy | |
1 prior chemotherapy regimen | 7 |
2 prior chemotherapy regimens | 10 |
High dose/ASCT | 5 |
Rituximab | 16 |
Prior radiotherapy | 8 |
Best response to last chemotherapy | |
Unknown | 1 |
Complete response | 7 |
Partial response | 3 |
Stable disease | 3 |
Progressive disease | 2 |
Inevaluable | 1 |
Number of sites of disease | |
1 | 5 |
2 | 3 |
3 | 3 |
4 (or more) | 6 |
Histology | |
DLBCL | 14 |
PMBCL | 1 |
Transformed diffuse large B-cell | 2 |
Baseline LDH | |
≤ULN | 6 |
>41–2.5 × ULN | 4 |
>42.5–5 × ULN | 3 |
>45 × ULN | 4 |
ECOG, Eastern Cooperative Oncology Group; ASCT, autologous stem cell transplant; DLBCL, diffuse large B-cell lymphoma; PMBCL, primary mediastinal B-cell lymphoma; LDH, lactate dehydrogenase; ULN, upper limit of normal.